Trial Profile
Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Anxiety; Postnatal depression
- Focus Therapeutic Use
- Acronyms IN-OXT
- 04 May 2023 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Planned End Date changed from 1 Jan 2023 to 1 May 2023.
- 13 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.